Grifols, S.A. (NASDAQ:GRFS) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $24.00.

Several equities analysts have weighed in on the company. BidaskClub raised Grifols, from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research downgraded Grifols, from a “buy” rating to a “hold” rating in a research report on Friday, May 5th. Goldman Sachs Group, Inc. (The) downgraded Grifols, from a “buy” rating to a “neutral” rating in a research report on Friday, June 30th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. Finally, HSBC Holdings plc downgraded Grifols, from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th.

Institutional investors have recently made changes to their positions in the stock. Huntington National Bank boosted its position in shares of Grifols, by 1.2% in the first quarter. Huntington National Bank now owns 6,704 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 77 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Grifols, during the first quarter valued at about $143,000. Quantbot Technologies LP boosted its position in shares of Grifols, by 86.8% in the first quarter. Quantbot Technologies LP now owns 8,122 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 3,774 shares during the last quarter. A.R.T. Advisors LLC bought a new position in shares of Grifols, during the fourth quarter valued at about $178,000. Finally, Quadrant Capital Group LLC boosted its position in shares of Grifols, by 168.1% in the first quarter. Quadrant Capital Group LLC now owns 11,990 shares of the biotechnology company’s stock valued at $220,000 after buying an additional 7,517 shares during the last quarter. Institutional investors and hedge funds own 22.11% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/18/grifols-s-a-nasdaqgrfs-receives-average-rating-of-hold-from-analysts.html.

Grifols, (NASDAQ:GRFS) traded down 0.95% during mid-day trading on Tuesday, reaching $20.80. 393,670 shares of the company were exchanged. Grifols, has a 1-year low of $14.27 and a 1-year high of $22.83. The stock has a market capitalization of $27.87 billion, a price-to-earnings ratio of 44.40 and a beta of 0.98. The stock’s 50-day moving average price is $21.24 and its 200-day moving average price is $19.29.

Grifols, Company Profile

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.